Aurinia Announces Change to Its Board of Directors
March 06 2015 - 07:00PM
Business Wire
Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”)
(NASDAQ:AUPH / TSX:AUP) today announced that Mr. Kurt von Emster
has tendered his resignation as a member of the Aurinia Board of
Directors, effective March 6th, 2015. This decision is driven by
Mr. von Emster’s departure from the employment of venBio LLC
(“venBio”), and the retained right of venBio to put forward a
nominee of their choice for election onto the Aurinia Board of
Directors.
“The Company very much wants to thank Kurt for his contributions
and thoughtful input over the course of his tenure. We are very
appreciative of everything that Kurt has brought to us,” said Dr.
Richard Glickman, Chairman of Aurinia’s Board of Directors.
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on
the global nephrology market. It is currently enrolling patients in
its Phase 2b clinical trial to evaluate the efficacy of its drug,
voclosporin, as a treatment for lupus nephritis (“LN”). LN is an
inflammation of the kidneys, that if inadequately treated can lead
to end-stage renal disease, making LN a serious and potentially
life-threatening condition.
Voclosporin is a novel and potentially best in class calcineurin
inhibitor (“CNI”) with extensive clinical data in over 2,600
patients in other indications. Voclosporin is made by a
modification of a single amino acid of the cyclosporine molecule (a
CNI approved for use in transplant patients since 1983). This
modification results in a more predictable pharmacokinetic and
pharmacodynamic relationship, an increase in potency vs.
cyclosporine, an altered metabolic profile, and potential for flat
dosing.
Aurinia also has development and commercialization partners in
Canada, Israel, South Africa and Greater China. Visit
www.auriniapharma.com, www.sedar.com and www.sec.gov for more
information.
Aurinia Pharmaceuticals Inc.Stephen Zaruby,
250-708-4293President & Chief Executive
Officerszaruby@auriniapharma.comInvestor & Media
Contact:Michael R. Martin, 250-708-4272Chief Operating
Officermmartin@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2023 to Mar 2024